Conditions: HIV
Keywords: Treatment experienced
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 710
Healthy volunteers: no

Brief summary:
The purpose of this study is to provide atazanavir or tenofovir-emtricitabine to HIV-infected subjects who have completed atazanavir or tenofovir-emtricitabine therapy on a previous BMS sponsored clinical trial and to collect long-term safety information on the treated population.

Detailed description:
Provide study drug for patients rolling off BMS ATV clinical trials in countries where these medications are not commercially available.

Arms:
arm 1: None arm 2: None arm 3: Ritonavir-boosted Lopinavir (LPV/RTV 400/100 mg) administered twice a day (BID) with Tenofovir/ Emtricitabine (TDF/FTC).

Interventions: intervention 1: Atazanavir intervention 2: Atazanavir/Ritonavir intervention 3: Tenofovir/Emtricitabine intervention 4: Lopinavir/ritonavir
Intervention descriptions: intervention 1: Tablets, Oral, 400 mg, once daily, indefinitely intervention 2: Tablets, Oral, 300/100 mg, once daily, indefinitely intervention 3: Tablets, Oral, 300/200 mg, once daily, indefinitely intervention 4: Tablets, Oral, 400/100 mg, twice daily, indefinitely

Protocol document: